TIDM0Y7T
RNS Number : 4723M
Societe Generale SA
11 May 2020
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing Société Générale
(Note 1) S.A.
Company dealt in Allergan plc
====================================
Class of relevant security US$0.0001 ordinary shares
to which the dealings
being disclosed relate
(Note 2)
====================================
Date of dealing 08/05/2020
====================================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
----------- ------ ---------- -----
(1) Relevant securities 1,545,947 0.47 46,789 0.01
----------- ------ ---------- -----
(2) Derivatives (other
than options) 0 0.00 1,356,491 0.41
----------- ------ ---------- -----
(3) Options and agreements
to purchase/sell 58,500 0.02 0 0.00
----------- ------ ---------- -----
Total *5,612,124 *1.70 1,403,280 0.43
----------- ------ ---------- -----
* Include the holding of 4,007,677 shares on borrow products
(b) Interests and short positions in relevant securities of the
company, other than the class dealt
in (Note 3)
Class of relevant Long Short
security:
Number (%) Number (%)
------- ---- ------- ----
(1) Relevant securities
------- ---- ------- ----
(2) Derivatives
(other than options)
------- ---- ------- ----
(3) Options and
agreements to purchase/sell
------- ---- ------- ----
Total
------- ---- ------- ----
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant Price per unit
securities USD (Note 5)
Purchase 100 193.09
------------------- ---------------
Purchase 100 193.12
------------------- ---------------
Purchase 100 192.92
------------------- ---------------
Purchase 99 191.96
------------------- ---------------
Purchase 1 191.96
------------------- ---------------
Purchase 100 192.19
------------------- ---------------
Purchase 100 192.89
------------------- ---------------
Purchase 100 192.37
------------------- ---------------
Purchase 18 192.85
------------------- ---------------
Purchase 1,386 193.01
------------------- ---------------
Purchase 3 193.01
------------------- ---------------
Purchase 100 192
------------------- ---------------
Purchase 100 192
------------------- ---------------
Purchase 100 191.92
------------------- ---------------
Purchase 100 191.91
------------------- ---------------
Purchase 100 192.2
------------------- ---------------
Purchase 100 192.9
------------------- ---------------
Purchase 100 192.49
------------------- ---------------
Purchase 100 192.59
------------------- ---------------
Purchase 100 191.93
------------------- ---------------
Purchase 7 193.01
------------------- ---------------
Purchase 33 193.01
------------------- ---------------
Purchase 361 193.2851
------------------- ---------------
Purchase 35 192.9
------------------- ---------------
Purchase 330 193.02
------------------- ---------------
Purchase 100 193.37
------------------- ---------------
Purchase 18 193.25
------------------- ---------------
Purchase 25 193.02
------------------- ---------------
Purchase 2,364 193.02
------------------- ---------------
Purchase 8 192.647
------------------- ---------------
Purchase 23,655 192.2396
------------------- ---------------
Sale 8 193.01
------------------- ---------------
Sale 2 192.04
------------------- ---------------
Sale 98 192.04
------------------- ---------------
Sale 95 192.09
------------------- ---------------
Sale 100 192.44
------------------- ---------------
Sale 100 192.06
------------------- ---------------
Sale 30 192.56
------------------- ---------------
Sale 100 192.55
------------------- ---------------
Sale 32 193.01
------------------- ---------------
Sale 100 192.45
------------------- ---------------
Sale 100 192.59
------------------- ---------------
Sale 100 192.62
------------------- ---------------
Sale 100 192.7
------------------- ---------------
Sale 100 192.67
------------------- ---------------
Sale 100 191.96
------------------- ---------------
Sale 100 192.44
------------------- ---------------
Sale 100 192.59
------------------- ---------------
Sale 15 192.67
------------------- ---------------
Sale 61 192.67
------------------- ---------------
Sale 24 192.67
------------------- ---------------
Sale 100 193.02
------------------- ---------------
Sale 17 192.96
------------------- ---------------
Sale 8 192.96
------------------- ---------------
Sale 414,700 193.02
------------------- ---------------
Sale 49 192.45
------------------- ---------------
Sale 51 192.45
------------------- ---------------
Sale 99 192.63
------------------- ---------------
Total Purchases 29,943
------------------- ---------------
Total Sales 416,489
------------------- ---------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant Price per
e.g. CFD (Note 6) securities unit USD
(Note 7) (Note 5)
-------------- ---------------------- ------------------ ----------
Equity Linked
Swap Decreased short 414,700 193.02
---------------------- ------------------ ----------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money
e.g. call purchasing, to which European paid/received
option varying the option etc. per unit
etc. relates (Note (Note
7) 5)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or
relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this
form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) Yes
Date of disclosure 11/05/2020
Contact name Société Générale
- Disclosure team
====================================
Telephone number +33 1 42 14 92 74
====================================
If a connected EFM, name
of offeree/offeror with
which connected
====================================
If a connected EFM, state
nature of connection (Note
10)
====================================
Ap23
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL
ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
(This form should be attached to Form 8.1(a) & (b)(i), Form
8.1(b)(ii) or Form 8.3,
as appropriate)
OPEN POSITIONS (Note 1)
Product Written, Number of relevant Exercise Type, Expiry
name, or purchased securities price e.g. American, date
e.g. call to which the (Note European
option option or derivative 2) etc.
relates
Listed American
Put Option Sale 40,000 175 options 15/01/2021
=============== ====================== ======== =============== ==========
Listed American
Put Option Sale 18,500 190 options 15/01/2021
=============== ====================== ======== =============== ==========
Notes
1. Where there are open option positions or open derivative
positions (except for CFDs), full details should be given. Full
details of any existing agreements to purchase or to sell must also
be
given on this form.
2. For all prices and other monetary amounts, the currency must be stated.
For full details of disclosur e requirements, see Rule 8 of the
Rules. If in doubt, consult the Panel.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEFIFFTEDILLII
(END) Dow Jones Newswires
May 11, 2020 04:30 ET (08:30 GMT)
Allergan (LSE:0Y7T)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Allergan (LSE:0Y7T)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
